What is Adipotide?
Adipotide (product:2mg*10vials/box) (a.k.a. FTPP or proapototic peptide) kills fat cells, plain and simple, by targeting the blood supply of those cells. Interestingly, adipotide is able to discern the blood vessels in fat cells from the blood vessels throughout the rest of the body and is therefore highly selective. Research in monkeys shows that adipotide not only causes weight loss, it actually boosts insulin sensitivity and offsets some of the effects of type 2 diabetes.
Adipotide before and after
Although Adipotide has been found to be effective in weight loss it is still in the clinical stages and more testing is needed. Some side effects have been logged in trials and the main concern includes dehydration. This means it can cause small kidney lesions and if this is not treated can cause kidney failure. A lot more clinical trials on humans are required to deal with problems like this. But, thanks to those in the research industry they work tirelessly to help find new cures and treatment for all conditions and diseases. That is why companies such as Peptides USA are here to serve the research trade to continue their excellent work to contribute to the medical establishment around the globe.
Will Adipotide Help You to Lose Weight?
If you want to lose weight, the peptide-like formula known as Adipotide may be exactly what you’re looking for. This peptide is classified as an experimental peptodomimetic and it was created in the USA in order to help people battle obesity. This ultra-modern weight loss treatment has been tested on rhesus monkeys. Many people believe that this peptide-like formula is the future of simple and stress-free weight loss.
Adipotide is often described as a peptide – however, it is not a peptide.
Adipotide is a peptodomimetic and it differs from a peptide in that it is made from small chains of matter (this matter is similar to protein). These chains are meant to simulate the performance of peptides. During tests, rhesus monkeys which were injected with this ultra-modern peptodomimetic decreased their overall body weight by eleven percent.
Adipotide decreased the body mass index, waist circumference and fatty deposits of lab monkeys.
How Does Adipotide Work?
Adipotide is designed for targeting specific blood vessels, supplying body fat (adipose tissue)with blood.
The process results in a shrinking on your vessels, forcing the fat cells to start
feeding on these vessels. All that mechanism leads to an apoptosis, which is a form of PCD that normally occurs in multicellular organisms. Typically, there are 2 receptors where adipotide binds: prohibitin and ANXA2. These are found in your blood vessels, and they accomplish the role of supplying your white adipose tissue.
This formula must be injected and it works by killing fat cells. When fat cells die, there is a decrease in volume within subcutaneous fat. This triggers weight loss. With Adipotide, cells are killed selectively, in a programmed fashion. They die because they are deprived of vital nutrients.
This formula works by destroying blood supply which contributes to fat cell growth. The process of targeted induction (Apoptosis), which kills cells, is the primary mechanism by which Adipotide supports weight loss. This ‘peptide’ has a couple of domains, both of which function separately in order to combat obesity.
The first domain is a homing domain and it works by targeting a membrane-associated protein which is known as Prohibitin. The homing domain works on adipose vascular endothelial cell matter. The second domain is a membrane-disrupting domain, which causes cell death by stopping or inhibiting mitochondrial membrane activity within targeted cells.
By keeping some fat cells from getting the nutrition that they need in order to stay alive, via the blood stream, this peptide-like formula provides quick weight loss results. While rhesus monkeys are the only test subjects to date, this experimental formula does hope to human subjects.
Monkeys who received Adipotide daily via injections experienced rapid and sustainable weight loss results. These test subjects lost twenty-percent of stomach fat within twenty-eight days. Some monkeys lost thirty-nine percent of their overall body fat, while others lost less. When fat cells in monkeys were killed with Adipotide, they were then metabolized by the body. Monkeys were treated with the drug for twenty-eight days and then underwent a twenty-eight day recovery period. For this reason, long-term weight loss results in rhesus monkeys are not available. However, short-term results do look promising.
Discover the Benefits of Adipotide
As a result of the laidback lifestyle of humans as well as the contemporary work modality, it is evident that the need for practising physical activity has significantly reduced, this causes many people to become obese and overweight.
Helps you to reduce your weight in just a few months.
The process results in the loss of a certain amount of abdominal fat mass.
Adipotide contains potentiating positive effects on insulin sensitivity as it improves it drastically. It’s reflected in using insulin efficiently on your body, which has been proven to have a positive effect on decreasing on elevated levels of blood glucose.
Adipotide maintains your health, and it allows energy use from the chemical nutrients your
body is receiving.
It regulates water by removing excess water and retaining it at the appropriate time.
It processes hormones, which is useful in the regulation of BP (blood pressure).
It balances the minerals in your body, which allows the correct functionality of your body.
This formula is designed to promote weight loss and this benefit has been confirmed via pre-clinical studies. As well, it offers hope to diabetics, as studies show that it reduces side effects of diabetic health conditions. Adipotide features an innovative mechanism when compared to other therapeutics which are available in the marketplace (or which are undergoing clinical trials).
Since Adipotide works without triggering psychological symptoms, it doesn’t cause modulation of neurotransmitter matter. As well, it doesn’t have an amphetamine-type mechanism. Men and women who utilize Adipotide may therefore access benefits without a high risk of gastrointestinal side effects.
Side Effects of Adipotide
Rhesus monkeys displayed high energy levels and general vitality while they were being treated with this peptide-like formula. They didn’t demonstrate any gastrointestinal discomfort or lose their appetites during therapy with Adipotide. This lack of negative side effects is in contrast to that of many approved drugs which minimize the absorption of lipids within the intestines.
However, this formula did appear to act on the kidneys. Negative impact on renal function was found to be reversible by altering dosage amounts. None of the test monkeys suffered from long-term kidney damage, as researchers adjusted their dosages in order to improve renal function.
The main problem experienced by rhesus monkeys, with regard to renal function, was the growth of compact kidney lesions which might have the capacity to cause kidney failure if they weren’t treated.
This formula may also trigger dehydration. Dehydration is a factor in kidney failure and also has the capacity to trigger an array of other health problems.
Bodybuilders Are Interested in Adipotide
Bodybuilders typically have a lot of experience with peptides and they have particular interest in this one. They know from experience that peptides are powerful formulas which allow them to change their bodies with a mind to accessing an assortment of results, from faster muscle mass growth to superior fat-burning power to optimal muscle recovery.
As well, peptides may help bodybuilders to avoid the negative side effects of anabolic steroid cycles. For this reason, many bodybuilders are interested in trying out this peptide-like formula as soon as they can. Some have already experimented with synthed versions of the formula, with mixed results. During the cutting phase of bodybuilding, when men and women need to reduce body fat without losing muscle, a formula such as Adipotide could provide practical benefits.
Most interested parties are waiting for results from clinical studies which planned for human subjects, in order to see how Adipotide acts on human bodies. Planned studies for this peptide-like formula include a study which will measure the benefits of Adipotide as a cancer treatment and a study which will be focused on determining the weight loss properties of this injectable.
Adipotide is a new formula and more research on human subjects will be needed before it’s made available to those who want to explore its weight loss and secondary health advantages.
It is possible to buy this experimental weight loss “peptide” online. If you are interested in doing so, be aware of the facts before you place an order. You need to know that this formula is experimental and that studies on human test subjects have not been performed yet. Waiting for FDA approval of this formula may be the safest way to proceed. Synthed formulas are not the real thing and they present risks.
For now, keep looking out for news stories on Adipotide. As well, consider checking out peptides online. There are a range of them which are already FDA-approved and which help to support weight loss, by sparking the production of natural hormones. Synthetic peptides are a futuristic approach to creating a better body and many of them are available to buy online, with or without a prescription. In addition, many reputable online retailers offer customers to buy these formulas for prices which are really reasonable.
Mixing and our recommended dosage
You inject 2ml water into the vial of Adipotide from the water vial. 1 full syringe is 1ml. You then wait for the vial powder content to dissolve ON ITS OWN. DO NOT SHAKE THE VIAL TO MIX POWDER. Once dissolved and clear in colour you draw out 0.3 on the syringe each morning before breakfast and inject it into the tummy under the skin into the fatty skin layer. A vial should last 7 days.
How Adipotide Works
What Are the Results and Benefits of Adipotide?
Molecular Formula: C152H252N44O42
Molecular Weight: 2611.41 g/mol
1. Adipotide And Fat Loss
Adipotide was developed and placed into phase I clinical trials in 2011 to investigate its ability to kill fat cells. Tests in rhesus monkeys revealed that adipotide causes targeted apoptosis in the blood vessels of white adipose tissue (fat). Without a blood supply, the fat cells simply died. The net result was rapid weight loss, rapid decrease in body mass index (BMI), and improved insulin resistance characteristics. Interestingly, treatment with adipotide and subsequent fat loss not only improved weight, but actually contributed to changes in eating behavior. Monkeys who lost weight with adipotide also showed a decrease in food consumption.
A. Percent weight loss in control groups (blue) versus those treated with adipotide (two differing doses, shown in red)
B. Percent reduction in BMI (control versus treatment)
A. Shows the change in insulin requirements (area under the curve) for treated (red) and control (blue) groups. The AUC was calculated from an IVGTT test.
B. Shows the insulinogenic index for before and after in the treatment (red) and control (blue) groups. Treated groups show a dramatic decrease in insulin secretion.
C. Change in biscuit consumption in treated (red) and control (blue) groups.
The targeting of adipotide to the blood vessels serving fat cells may be mediated by a protein receptor called prohibitin. Prohibitin is a membrane protein that may only be found in blood vessels serving white fat and in cancer cells. It has been demonstrated that adipotide associates with this protein. If it turns out that prohibitin is found only in fat vasculature and cancer tissue, then adipotide testing will be responsible for identifying a fat-specific target that can be used not just for therapeutic purposes, but for diagnostic purposes as well.
2. Adipotide and Cancer
Prohibitin, the molecule that adipotide likely targets in fat cells, has been associated with certain types of cancer. Cancer cells are known to require substantial blood supplies in order to grow and metastasize. The ability to target prohibitin in cancer cells may provide for advanced therapies that target cancer without harming surrounding tissues.
3. Adipotide and Glucose Tolerance
Glucose tolerance is a term that refers to higher than normal levels of blood sugar. The condition is generally diagnosed with a blood test and confirmed by testing fasting glucose levels or by administering a glucose tolerance test in which a set amount of sugar is consumed and then blood levels of sugar are measured. Glucose tolerance is a proxy measure for diabetes, with increased glucose tolerance indicating a trend toward diabetes.
Treating elevated glucose levels can be done with diet and exercise, but these methods require dedication and motivation. They also take considerable time to have an effect. In general, most people with impaired glucose tolerance go on to develop overt type 2 diabetes and require drugs like metformin and, in some cases, insulin. Research into adipotide has revealed that the peptide produces rapid and weight-independent improvement in glucose tolerance. The latter part is critical, because it indicates that a reduction in white fat by adipotide is effective in reducing glucose tolerance regardless of the impact on weight. In other words, it is the fat loss that is important, not the weight loss. These findings not only open the pathway for developing new treatments for pre-diabetes and diabetes, they help to clarify and explain the mechanisms that lead to diabetes in the first place.
There is some argument as to whether adipotide directly causes fat loss or simply decreases food intake which indirectly leads to fat loss. It is likely that adipotide directly causes fat loss. This hypothesis is supported by the fact that the peptide causes changes in fat cell density without causing weight loss and affects glucose tolerance without causing weight loss.
Future Adipotide Research
The primary area of adipotide research is in fat loss and diabetes. The peptide targets specific cells in the blood vessels that supply fat tissue, causing those blood vessels to die and, as a result, causing the fat cells they supply to die. Adipotide is an anti-angiogenic peptide, which means it targets blood vessels. Anti-angiogenic molecules are of keen interest right now in the treatment of cancer. There is limited, but promising research, on the role of adipotide in cancer.
Adipotide exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. Adipotide for sale at Peptide Sciences is limited to educational and scientific research only, not for human consumption. Only buy Adipotide if you are a licensed researcher.
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Scientific Journal Author
Kirstin Barnhart, MD, lead author of “A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys,” is Associate Director, Senior Pathologist at AbbVie – a leading pharmaceutical research and development company. Dr. Barnhart led a study where the treatment with adipotide induced targeted apoptosis within blood vessels of white adipose tissue and resulted in rapid weight loss and improved insulin resistance in obese monkeys. Magnetic resonance imaging and dual-energy x-ray absorptiometry confirmed a marked reduction in white adipose tissue.
Kirstin Barnhart, MD is being referenced as one of the leading scientists involved in the research and development of Adipotide. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Barnhart is listed in  under the referenced citations.
-  K. F. Barnhart et al., “A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys,” Sci. Transl. Med., vol. 3, no. 108, p. 108ra112, Nov. 2011. [PubMed]
-  M. G. Kolonin, P. K. Saha, L. Chan, R. Pasqualini, and W. Arap, “Reversal of obesity by targeted ablation of adipose tissue,” Nat. Med., vol. 10, no. 6, pp. 625–632, Jun. 2004. [PubMed]
-  F. I. Staquicini et al., “Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients,” Proc. Natl. Acad. Sci. U. S. A., vol. 108, no. 46, pp. 18637–18642, Nov. 2011. [PubMed]
-  D.-H. Kim et al., “Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium,” Diabetes, vol. 61, no. 9, pp. 2299–2310, Sep. 2012. [PubMed]
-  L. Criscione, “Comment on ‘a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys,’” Sci. Transl. Med., vol. 4, no. 131, pp. 131le2; author reply 131lr2, Apr. 2012. [PubMed]
-  Barnhart KF, Christianson DR, Hanley PW, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011;3(108):108ra112. doi:10.1126/scitranslmed.3002621 [PMC]
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.